Back to Journals
Cancer Management and Research
Associate Director of the Tisch Cancer Institute for Clinical Cancer Genetics and Precision Oncology, The Icahn School of Medicine at Mount Sinai, New York, United States
Editor-in-Chief: Dr Kenan Onel
Dr Onel is an expert in clinical cancer genetics and oversees an active research program to investigate the role of genetics in cancer risk and response to therapy. He is a graduate of Yale University and received both an MD and a PhD in molecular biology from Cornell University Medical College. He completed a residency in Pediatrics at Babies and Children's Hospital of New York (Columbia University), a clinical fellowship in Pediatric Hematology/Oncology at the Memorial Sloan-Kettering Cancer Center, and a post-doctoral fellowship in Cancer Genetics at Rockefeller University. Dr Onel then joined the faculty of The University of Chicago in 2004 where he was an Associate Professor of Pediatrics and Director of the Familial Cancer Clinic. In 2016, Dr Onel was recruited to the Zucker School of Medicine at Hofstra/Northwell where he was Professor of Pediatrics and Genetics and Chief of Medical Genetics and Human Genomics. As of February 2019, Dr Onel joined the Icahn School of Medicine at Mount Sinai as Professor of Genetics and Genomic Sciences, and Associate Director of the Tisch Cancer Institute for Clinical Cancer Genetics and Precision Oncology.
Oncology Institute, Chaim Sheba Medical Center, Israel
Associate Editor: Raphael Catane
Residency in Medical Oncology at the Hadassah Medical Center in Jerusalem and further training in Roswel Park Cancer Institute in Buffalo, N.Y. and at the National Cancer Institute (NCI), NIH at Bethesda, Md, U.S.A. In 2001 Raphael Catane became head of the largest cancer center in Israel, at Sheba Cancer Center in Tel-Hashomer (Near Tel-Aviv), and was nominated as Clinical Professor of Oncology in Tel-Aviv University , now Professor Emeritus. His clinical Interests are: Management of solid tumors, breast cancer genetics, Immunotherapy, drug development and palliative care. His achievements include: Participation in the development of new anticancer agents. Founder of the ESMO Palliative Care Working Group and the Designated Cancer Centers program, for integration of Palliative Care.
Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Italy
Associate Editor: Antonella D'Anneo
Dr. D’Anneo earned a Master Degree with full marks and honors in Biological Sciences (curriculum in molecular biology) from the University of Palermo in 2000 and obtained a Ph.D. in Experimental Oncobiology in 2004.
She began her studies on the field of tumor biology, cell death mechanisms and biochemical pathways that can be activated in tumor cells. Her scientific production is characterized by manuscripts on researches performed to elucidate the mode of action of apoptotic drugs and the possible synergistic interactions when drugs are employed in combination studies. To complement the graduate training in biochemistry, Dr. D'Anneo obtained, as visiting scholar, a training at Rangos Research Center (Children's Hospital, School of Medicine, University of Pittsburgh, PA-USA). During this stage (2005-2007), she was directly involved in the study of Adenoviral and EIA (Equine infectious anemia) viruses in blocking cytokine-induced apoptosis in both human and murine pancreatic ß islets. She also took part in a research project concerning gene therapy approaches to determine tolerizzation of diabetic patients against the cells of islet donor.
During her career, she had acquired expertise in the study of many different types of cell death (apoptosis, necrosis, necroptosis, autophagy and anoikis) activable in vitro tumor systems and the role of oxidative stress in cancer. Dr. D’Anneo made significant contributions to researches on combinations of sesquiterpene lactones (parthenolide), HDAC inhibitors (SAHA, Trichostatin A and sodium butyrate), proteasome inhibitors (MG132, lactacystin and Velcade) and recombinant Trail in vitro studies for the treatment of many different cancer systems. She is also the co-inventor of a patent for combined therapies for the treatment of liver tumors.
In the recent years she was also focused on the study of the serpin proteinase inhibitor 9 (PI-9) in ER+ breast cancer cells and breast cancer stem-like cells.
She is currently an Assistant Professor in Biochemistry at the Department of Sciences and Biological, Chemical and Pharmaceutical Technologies, School of Basic and Applied Sciences, University of Palermo and serves as mentor of PhD and students of the MSc in Molecular and Health Biology.
Department of Internal Medicine, Division of Hematology, Istanbul University, Cerrahpasa Faculty of Medicine, Turkey
Associate Editor: A. Emre Eşkazan, MD
Dr. Eskazan is an Associate Professor of Internal Medicine/Hematology. He obtained his MD from Cerrahpasa Faculty of Medicine, Istanbul University in 1999. He finished internal medicine residency and hematology fellowship at the same institution in 2005 and 2010, respectively. His research interests have been focussed on chronic myeloid leukemia, acute myeloid leukemia, and other myeloproliferative neoplasms. In 2015, he worked as a visiting physician at the University of Texas, MD Anderson Cancer Center, Department of Leukemia. Dr. Eskazan has more than 90 papers published in peer reviewed journals. He is currently working at the Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa.
Prof. Dr. Fernandes
Faculdade Ciências e Tecnologia, UCIBIO, FCT/UNL, Portugal
Associate Editor: Prof. Dr. Fernandes
Dr. Fernandes is an Assistant Professor at Faculdade de Ciências e tecnologia, Universidade NOVA de Lisboa, Portugal. She obtained her PhD in Biotechnology from Instituto Superior Técnico, Universidade de Lisboa after earning her graduation degree in Chemical Engineering/Biotechnology also from the same institution in Lisbon, Portugal. Dr. Fernandes is an expert research scientist that combines chemistry, biochemistry, molecular biology and human molecular genetics. Her research interests have been focussed on cancer diagnostics, biomarkers identification and validation, drug screen and validation using in vitro and in vivo models and in the development of novel combinatorial therapies. In 2013, she has translated part of her research into a private Diagnostics company. Dr. Fernandes has 5 book chapters, and more than 65 papers published in peer reviewed journals. Dr. Fernandes serves as reviewer for more than 8 reputable journals.
Department of Radiation Oncology, The Ohio State University, United States
Associate Editor: Dr Naduparambil K. Jacob
Dr. Jacob is an Assistant Professor of Radiation Oncology at The Ohio State University (OSU) Wexner Medical Center, USA. He is a member of translational therapeutics program at the OSU Comprehensive Cancer Center (OSUCCC). He received PhD in Biology from University of Tuebingen, Germany and completed his postdoctoral training at University of Cincinnati College of Medicine, USA. Dr. Jacob’s postdoctoral studies have contributed significantly to our current understanding of DNA structure at chromosome ends, particularly the biochemistry of generation of chromosome ends, resolving the structure of telomere chromatin at the molecular level. His laboratory at OSUCCC studies mechanism of radiation resistance in aggressive tumors and cancer metastasis. His research group uses rodent models for mechanistic studies and specimens from patients who received radiation therapy for correlative studies. His recent research led to the development of miRNA based radiation biodosimetry, which resulted in high impact publications, patents and secured research funding from US National Institutes of Health (NIH), Department of Defense (DOD) and National Aeronautics and Space Administration (NASA). Current research projects include developing miRNAs and long non-coding RNAs as biomarkers of normal tissue toxicity, tumor and organ specific responses, early prediction of delayed/late effects such as pneumonitis and fibrosis in patients receiving radiation therapy and also in victims of radiation accidents. Dr. Jacob has served in various grant review panels and editorial boards of multiple journals and is active in educational activities at the institutional and national level.
Department of Pathology, Chi Mei Medical Center, Taiwan
Associate Editor: Chien-Feng Li
Dr Li is the Chair of Department of Pathology, Chi Mei Medical Center, and he also serves as a professor at Southern Taiwan University of Science and Technology, as well as a joint-appointment associate investigator at National Institute of Cancer Research (Taiwan). He got his Medical Degree from Kaohsiung Medical University in 2002. In 2012, he got his Doctor of Philosophy in biomedical sciences from National Sun Yat-sen University. As a physician scientist, his current research interest is integrative analysis of genetic, epigenetic, and expression alternations during cancer progression and metastasis, with special emphasize on sarcomas and therapy-resistant cancers. With the opportunities to integrate large-scaled clinical samples and advanced functional evaluations, he has been more focused on potential therapeutic opportunities of oncogenic metabolic transformations and the mechanisms how the metabolic characters of cancer implicate tumor progression.
Indiana University School of Medicine, United States
Associate Editor: Dr Harikrishna Nakshatri
Dr. Nakshatri’s research interests are on heterogeneity in normal breast, the mechanisms of anti-estrogen resistance and metastasis in breast cancer. Ongoing research in his lab includes elucidating the mechanisms by which the serine/threonine kinase AKT alters estrogen signaling and confers anti-estrogen resistance. His laboratory has identified and commercialized biomarkers that may predict response to anti-estrogen therapy. His laboratory was the first to demonstrate constitutive activation of NF-kappaB in a subset of breast cancer. Activated NF-kappaB confers chemotherapy resistance and enhances metastasis. His laboratory is also investigating the mechanisms of organ-specific metastasis and the role of cancer stem cells in chemoresistance and metastasis. Using the normal breast tissue from Susan G. Komen for the Cure Tissue Bank, his group has shown ethnicity-dependent and ethnicity-independent heterogeneity in normal breast. His group has also established a culturing method to grow tumors, and tumor adjacent-normal, and metastasis to genomically characterize tumors/metastasis at single cell level. NIH, Department of Defense, American Cancer Society, Susan G. Komen for Cure, Department of Veterans Affairs and other private foundations funded his research. He is the author or co-author of >120 publications with >12,500 citations. He has served/serving in scientific review committees of NIH, Department of Defense, Italian Association for Cancer Research, and Susan G. Komen for Cure. He is one among 52 breast cancer researchers who serve as Susan G. Komen Scholars (2010-2020). He is currently a member of the NIH Cancer Molecular Pathobiology Study Section. He is also in the editorial boards of scientific journals and an Associate Editor of Cancer Research. He has trained over 20 post-doctoral fellows, surgical residents, and medical students. In his role as the Associate Director of Education at the Indiana University Simon Cancer Center (IUSCC), he is responsible for developing educational activities of the cancer center and a training program in cancer biology.
Biotechnology, CSIR-Institute of Himalayan Bioresource Technology, Palampur, India, India
Associate Editor: Riruraj Purohit (PhD)
Senior Scientist, Biotechnology Division, CSIR-Institute of Himalayan Bioresource Technology (Council of Scientific & Industrial Research) Palampur, India
Dr. Rituraj Purohit finished his PDF at Human Genetic Foundation (HuGeF-Torino) and worked as a Associate Professor at VIT University, India. Currently he is working as a Senior Scientist (Computational Biology), Biotechnology Division, CSIR-Institute of Himalayan Bioresource Technology (Council of Scientific & Industrial Research) India. His scientific interests focus on range of issues related to structural bioinformatics. By adopting multidisciplinary approach combines first-principle physics with the analysis of biological systems such as 3-dimensional structure of proteins, protein-drug complex and nucleic acids, He would like to observe that how certain mutation alter the dynamics behavior of onco-proteins and its interaction with other molecules. He is very much interested in molecular folding, evolution, and binding interactions, and structure/function relationships of experimentally solved structures and from computational models.
Dr. Purohit has published a number of original and review articles, including publications as first and corresponding author. He is also serving as the editor and associate editor of a number of international medical journals.
Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China (PRC)
Associate Editor: Beicheng Sun
Dr. Sun is a professor and surgeon at Nanjing University where he serves as the Vice president of The Affiliated Drum Tower Hospital of Nanjing University Medical School. In 2001, he obtained his MD-PhD degree in Nanjing Medical University, China. As a postdoctoral fellow at The University of Texas Health Science Center at San Antonio, he devoted in the telomerase-related cancer research. As a surgeon, he is skilled in liver transplantation and Hepatectomy. Dr. Sun's researches mainly focused on inflammatory-related carcinogenesis. His team discovered the potential therapeutic values and mechanistic roles of cytokines in hepatocarcinogenesis including IL-22, IL-17A, and IL-1α, etc. His team also explored the cell signaling involving in the malfunction of tumor infiltrated Leucocytes (TILs), they clarified the roles of PTPRO/STAT3, PTPRO/NF-κB, and Lnc-EGFR/EGFR/AP-1 signaling in the immunosuppressive-transform of T cell and macrophage. His current research interests are inflammatory related metabolic disorders in TILs, aiming to clarify the metabolism-related links in T cell exhausting and NK cell malfunction. Meanwhile, clinical trials of immunotherapy are in procession using CAR-T and CRISPR-Cas9. Dr. Sun is the Yangtze River Scholar Professor of Chinese Ministry of Education, and he also obtained a National Science Fund for Distinguished Young Scholars. He is an Associate Editor of Plos One and Associate Editor of World Journal of Gastroenterology, the member of the Youth Committee of Chinese Organ Transplantation Society of Chinese Medical Association and the Executive Committee of Chinese Society of Liver Cancer, Chinese Anti-Cancer Association.
Department of Cell Systems & Anatomy, University of Texas Health Science Center, United States
Associate Editor: Dr. LuZhe Sun
Dr. LuZhe Sun received his Ph.D. in Physiology from Rutgers University and UMDNJ-Robert Wood Johnson Medical School in 1990 and obtained his postdoctoral training in Baylor College of Medicine in the US. He is currently Professor, Dielmann Endowed Chair in Oncology, and Associate Director for Basic Research at his NCI-designated cancer center. Dr. Sun’s research is focused on investigating molecular mechanisms of tumorigenesis and metastasis, and novel experimental therapeutics in various models of carcinomas. His research has been supported with multi-million dollar grants from NIH, DOD, CPRIT, and other private foundations. He is an elected AAAS Fellow.
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, China (PRC)
Associate Editor: Xueqiong Zhu
Dr. Zhu got a Master Degree in clinical medicine from Tianjin Medical University, P.R.China in 2001 and received her Ph.D. from Medical College of Zhejiang University, P.R.China in 2004. Dr. Zhu is Currently Professor, Chief Physician, and Director for the Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, P.R.China. Her research interests focus on the mechanisms, diagnosis and therapy of cervical carcinoma, ovarian carcinoma and uterine leiomyoma. Dr. Zhu has published more than 170 original and review articles and has 11 authorized patents. She has undertaken more than 30 different-level research projects, including 4 national and 6 provincial, and has also gained 10 science and technology awards of national and provincial level.
Laure Aurelian, Professor of Pharmacology and Microbiology and Immunology, Department of Pharmacology, University of Maryland School of Medicine, Baltimore Maryland; Senior advisor for Faculty Development, Stanford School of Medicine, Stanford, California, USA
Prof. Franky Leung Chan, Professor, Cancer Biology and Experimental Therapeutics, School of Biomedical Sciences, Chinese University of Hong Kong, Shatin, Hong Kong
Professor Brendon Coventry, Associate Professor of Surgery, Discipline of Surgery, University of Adelaide, Royal Adelaide Hospital, South Australia, Australia 5000
Bilikere Dwarakanath, Shanghai Proton and Heavy Ion Center, Pudong, Shanghai 201321, China.
Alfio Ferlito, Professor of Otorhinolaryngology-Head and Neck Surgery, Coordinator of the International Head Neck Scientific Group (www.IHNSG.com)
Randall F Holcombe, MD, MBA, Director, University of Hawaii Cancer Center, Honolulu, HI, USA
Gary L Johanning, Program Director - Viral Oncology & Immunology, Discovery Biology Section, SRI International, Menlo Park, CA, USA
Cheryl L. Jorcyk, Director, Clinical/Translation Research, Professor of Biological Sciences, Boise State University, Boise, ID, USA
Kattesh V Katti, Distinguished Curators’ Professor of Radiology and Physics; Margaret Proctor Mulligan Distinguished Chair; Professor of Cancer Research; Director, Institute of Green Nanotechnology, University of Missouri Medical School, Columbia, MO, USA
Evan Keller, Professor, Department of Urology and Pathology, University of Michigan, Ann Arbor, MI, USA
Thomas V Merluzzi, Professor, Department of Psychology, Laboratory for Psycho-oncology Research, University of Notre Dame, Notre Dame, IN, USA
Silvana Morello, PhD, Assistant Professor of Clinic Pharmacology and Immunopharmacology, Department of Pharmacy, University of Salerno, Salerno, Italy.
Rudolph M Navari, Professor of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham School of Medicine; Senior Scientist, Experimental Therapeutics Program, UAB Comprehensive Cancer Center, Birmingham, AL, USA
Eileen M. O'Reilly, M.D., Section Head Hepatopancreaticobiliary & Neuroendocrine Cancers, Gastrointestinal Oncology Service; Associate Director, David M. Rubenstein Center for Pancreatic Cancer Research; Attending Physician, Member, Memorial Sloan Kettering Cancer Center; Professor of Medicine, Weill Cornell Medical College, New York, NY, USA
Errol Philip, Notre Dame Laboratory for Psycho-oncology Research, University of Notre Dame, Notre Dame, IN, USA
Johnson Stanslas, Professor, Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Malaysia
Friedrich Stölzel, Department of Internal Medicine I, University Hospital Dresden, Germany
Prof. Andrzej Stepulak, MD.Ph.D, Department of Biochemistry and Molecular Biology, Medical University in Lublin, Lublin, Poland.
Armin D Weinberg, Clinical Professor, Baylor College of Medicine; Adjunct Professor, Rice University; Faculty Affiliate, Texas A&M University School of Public Health, TX, USA
Kexin Xu, Assistant Professor, Department of Molecular Medicine, the University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
Prof. Dr. Zhang
Jing Zhang, Professor in Department of Pathology, State Key Laboratory of Tumor Biology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China.